Stockscreener 앱 받기
22.63
9.38%
1.94
시간 외 거래:
23.08
0.45
+1.99%
전일 마감가:
$20.69
열려 있는:
$21.45
하루 거래량:
547.79K
Relative Volume:
1.69
시가총액:
$1.25B
수익:
$29.71M
순이익/손실:
$-69.15M
주가수익비율:
-44.11
EPS:
-0.513
순현금흐름:
$-52.28M
1주 성능:
+19.23%
1개월 성능:
+15.75%
6개월 성능:
+60,733%
1년 성능:
+60,733%
1일 변동 폭
$21.02
$23.34
1주일 범위
$18.25
$23.45
52주 변동 폭
$14.72
$29.16
Aktis Oncology Inc Stock (AKTS) Company Profile
명칭
Aktis Oncology Inc
전화
978-237-4380
주소
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
22.63 | 1.14B | 29.71M | -69.15M | -52.28M | -0.513 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 개시 | H.C. Wainwright | Buy |
| 2026-02-03 | 개시 | BofA Securities | Buy |
| 2026-02-03 | 개시 | JP Morgan | Overweight |
| 2026-02-03 | 개시 | Leerink Partners | Outperform |
| 2026-02-03 | 개시 | TD Cowen | Buy |
| 2024-01-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-09-06 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-24 | 개시 | B. Riley Securities | Buy |
| 2021-02-02 | 재확인 | Craig Hallum | Buy |
| 2021-01-15 | 재확인 | Craig Hallum | Buy |
| 2019-09-18 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-07-10 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-13 | 재확인 | Craig Hallum | Buy |
| 2019-02-05 | 재확인 | Craig Hallum | Buy |
| 2019-02-05 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-12-18 | 개시 | Craig Hallum | Buy |
| 2018-11-30 | 개시 | Lake Street | Buy |
| 2018-06-22 | 개시 | Loop Capital | Buy |
| 2018-02-09 | 개시 | Drexel Hamilton | Buy |
모두보기
Aktis Oncology Inc 주식(AKTS)의 최신 뉴스
This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Raymond James initiates Aktis Oncology stock coverage with buy rating By Investing.com - Investing.com Canada
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - AOL.com
Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Rezolve AI, Bakkt, Seagate And Other Big Stocks Moving Higher On Friday - Benzinga
Aktis Oncology: Mini-Proteins With A Targeted Punch (NASDAQ:AKTS) - Seeking Alpha
AKTS: Advancing novel radiopharmaceuticals with strong early data, robust supply, and pipeline growth - TradingView
H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $35 - Moomoo
H.C. Wainwright Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $35 - Moomoo
AKTS Maintained by HC Wainwright & Co. -- Price Target Raised to $35 - GuruFocus
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Bank of America Securities Remains a Buy on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
AKTS Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressGrowth Acceleration Report - newsline.com
Aktis Oncology CEO to present new targeted radiopharmaceuticals at Jefferies Healthcare Conference - Pluang
Aktis Oncology to Present at the Jefferies Global Healthcare Conference - The Manila Times
a16z Capital Management, L.L.C.'s Aktis Oncology Inc(AKTS) Holding History - GuruFocus
A Look At Aktis Oncology (AKTS) Valuation After Recent Share Price Rebound - Yahoo Finance
Top Premarket Gainers - Moomoo
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors - The Manila Times
Aktis Oncology reports promising first-in-human... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Aktis Oncology to Present Promising AKY-2519 Data Targeting B7-H3 Tumors at 2026 ASCO Annual Meeting - Quiver Quantitative
Aktis Oncology Reports First-in-Human Clinical Imaging and - GlobeNewswire
New cancer agent shows high tumor uptake, limited healthy exposure - Stock Titan
Top Cybin (HELP) Competitors 2026 - MarketBeat
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Blue Owl discloses 5.92% stake in Aktis Oncology (AKTS) in Schedule 13G - Stock Titan
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company - The Motley Fool
AKTS: Advancing miniprotein radioconjugates for cancer, with strong pipeline, partnerships, and cash runway - TradingView
AKTS: Miniprotein radiopharmaceuticals advance in oncology with strong clinical and financial momentum - TradingView
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge - BioSpace
William Blair Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
TD Cowen Maintains Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
Aktis: Q1 Earnings Snapshot - 10TV
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 - The Manila Times
Aktis Oncology Q1 net loss widens on increased IPO-related expenses - TradingView
Aktis Oncology (NASDAQ: AKTS) boosts cash to $538.5M after IPO despite higher Q1 loss - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aktis Oncology (NASDAQ: AKTS) boosts cash with IPO, posts wider Q1 loss - Stock Titan
Earnings Flash (AKTS) Aktis Oncology, Inc. Reports Q1 Revenue $3.2M - Moomoo
Cancer radiopharma firm Aktis adds $365M IPO cash, funds to 2029 - Stock Titan
Aktis Oncology to Present at the BofA Securities Health Care Conference - GlobeNewswire
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer By Investing.com - Investing.com India
Aktis Oncology CEO to present new targeted radiopharmaceuticals at BofA Health Care Conference - Pluang
William Blair Initiates Aktis Oncology(AKTS.US) With Buy Rating - Moomoo
AKTS: AKY-2519 advances in Phase I-B trials for mCRPC and B7H3-expressing tumors, with key data ahead - TradingView
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors - MarketBeat
Aktis initiates phase 1b trial of AKY-2519 in prostate cancer - Investing.com
Aktis opens prostate cancer study as it broadens AKY-2519 testing - Stock Titan
Aktis Oncology Initiates Phase 1b Clinical Trial for - GlobeNewswire
UCB strikes up to $2.2B Candid deal, spotlighting Two River and Vida - Stock Titan
Aktis Oncology Inc (AKTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aktis Oncology Inc 주식 (AKTS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| GADICKE ANSBERT | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
1,112,777 |
20,029,986 |
10,260,064 |
| EcoR1 Capital, LLC | Director |
Jan 12 '26 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
4,348,658 |
| Vida Ventures II, LLC | 10% Owner |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
| Kim Helen Susan | Director |
Jan 12 '26 |
Buy |
18.00 |
835,000 |
15,030,000 |
5,671,825 |
1.27%
1.43%
자본화:
|
볼륨(24시간):